Dr. Keren Paz is an experienced scientist executive with demonstrated leadership and expertise in precision medicine, preclinical and clinical drug development, and business development. With over 20 years of experience, Keren has a profound, applicable scientific and translational know-how and is passionate about building vibrant, focused, and enthusiastic teams that are dedicated to making a remarkable impact on oncology drug development and patient care. Prior to joining Nectin Therapeutics, as the Chief Development Officer in January 2021, Keren held various leadership roles in biopharma companies, including ImClone Systems, Eli Lilly, Champions Oncology, Fortress Biotech and Stelexis Therapeutics. Keren holds a Ph.D. from The Weizmann Institute of Science and was trained at The Rockefeller University and MSKCC under the mentoring of world-renowned scientists and Nobel laureates.